Comprehensive Update on Synthetic Aspects of Bosentan Derivatives

dc.contributor.authorPanchal, Jigar
dc.contributor.authorPanchal, Ashima
dc.contributor.authorJain, Sonika
dc.contributor.authorJain, Pankaj Kumar
dc.contributor.authorDwivedi, Jaya
dc.contributor.authorSharma, Swapnil
dc.date.accessioned2024-01-21T10:33:01Z
dc.date.accessioned2024-08-13T11:16:44Z
dc.date.available2024-01-21T10:33:01Z
dc.date.available2024-08-13T11:16:44Z
dc.date.issued2022-05-11T00:00:00
dc.description.abstractBosentan and its analogues were first reported as endothelin (ET) receptor antagonists in US patent No. 5, 292,740 in 1994. Bosentan synthesis has been reported by employing different methods from the reaction between (4,6-dichloro-5-(2-methoxyphenoxy)-2,2'-bipyrimidine and 4-(tert-butyl) benzenesulfonamide and 4-(tert-butyl)-N-(6-chloro-5-(2-methoxyphenoxy)-[2,2'-bipyrimidin]-4-yl) benzenesulfonamide in the form of different salts like potassium salt, ammonium salt, sodium salt, and free, on its reaction with ethylene glycol. Several changes have been observed in the chemistry of the involved intermediate synthesis, particularly coupling chemistry, to produce bosentan derivatives with high purity and yield. � 2023 Bentham Science Publishers.en_US
dc.identifier.doi10.2174/1389557522666220510113702
dc.identifier.issn13895575
dc.identifier.urihttps://kr.cup.edu.in/handle/32116/3241
dc.identifier.urlhttps://www.eurekaselect.com/204521/article
dc.language.isoen_USen_US
dc.publisherBentham Science Publishersen_US
dc.subjectantagonisten_US
dc.subjectBosentanen_US
dc.subjectcatalysisen_US
dc.subjectendothelinen_US
dc.subjectone-poten_US
dc.subjecttracleeren_US
dc.titleComprehensive Update on Synthetic Aspects of Bosentan Derivativesen_US
dc.title.journalMini-Reviews in Medicinal Chemistryen_US
dc.typeShort surveyen_US
dc.type.accesstypeClosed Accessen_US

Files